JP5887672B2 - ビタミンｄ関連化合物の１−デオキシ類似体 - Google Patents

ビタミンｄ関連化合物の１−デオキシ類似体 Download PDF

Info

Publication number
JP5887672B2
JP5887672B2 JP2012549078A JP2012549078A JP5887672B2 JP 5887672 B2 JP5887672 B2 JP 5887672B2 JP 2012549078 A JP2012549078 A JP 2012549078A JP 2012549078 A JP2012549078 A JP 2012549078A JP 5887672 B2 JP5887672 B2 JP 5887672B2
Authority
JP
Japan
Prior art keywords
alkyl
alkenyl
compound
vitamin
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012549078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518812A5 (enExample
JP2013518812A (ja
Inventor
ゲイリー エイチ ポズナー
ゲイリー エイチ ポズナー
リンゼイ シー ヘス
リンゼイ シー ヘス
アルヴィン エス カリンダ
アルヴィン エス カリンダ
レイチェル ディー スラック
レイチェル ディー スラック
ウッタム サハ
ウッタム サハ
ピー マーティン ペトコヴィッチ
ピー マーティン ペトコヴィッチ
Original Assignee
シトクロマ インコーポレイテッド
シトクロマ インコーポレイテッド
ザ ジョンズ ホプキンズ ユニヴァーシティー
ザ ジョンズ ホプキンズ ユニヴァーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シトクロマ インコーポレイテッド, シトクロマ インコーポレイテッド, ザ ジョンズ ホプキンズ ユニヴァーシティー, ザ ジョンズ ホプキンズ ユニヴァーシティー filed Critical シトクロマ インコーポレイテッド
Publication of JP2013518812A publication Critical patent/JP2013518812A/ja
Publication of JP2013518812A5 publication Critical patent/JP2013518812A5/ja
Application granted granted Critical
Publication of JP5887672B2 publication Critical patent/JP5887672B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012549078A 2010-01-13 2011-01-13 ビタミンｄ関連化合物の１−デオキシ類似体 Expired - Fee Related JP5887672B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29474110P 2010-01-13 2010-01-13
US61/294,741 2010-01-13
PCT/US2011/021129 WO2011088209A2 (en) 2010-01-13 2011-01-13 1-deoxy analogs of vitamin d-related compounds

Related Child Applications (3)

Application Number Title Priority Date Filing Date
JP2015136522A Division JP2015212294A (ja) 2010-01-13 2015-07-07 ビタミンｄ関連化合物の１−デオキシ類似体
JP2015136520A Division JP2016006055A (ja) 2010-01-13 2015-07-07 ビタミンｄ関連化合物の１−デオキシ類似体
JP2015136521A Division JP2016006056A (ja) 2010-01-13 2015-07-07 ビタミンｄ関連化合物の１−デオキシ類似体

Publications (3)

Publication Number Publication Date
JP2013518812A JP2013518812A (ja) 2013-05-23
JP2013518812A5 JP2013518812A5 (enExample) 2014-03-06
JP5887672B2 true JP5887672B2 (ja) 2016-03-16

Family

ID=44010128

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012549078A Expired - Fee Related JP5887672B2 (ja) 2010-01-13 2011-01-13 ビタミンｄ関連化合物の１−デオキシ類似体
JP2015136521A Pending JP2016006056A (ja) 2010-01-13 2015-07-07 ビタミンｄ関連化合物の１−デオキシ類似体
JP2015136520A Pending JP2016006055A (ja) 2010-01-13 2015-07-07 ビタミンｄ関連化合物の１−デオキシ類似体
JP2015136522A Pending JP2015212294A (ja) 2010-01-13 2015-07-07 ビタミンｄ関連化合物の１−デオキシ類似体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015136521A Pending JP2016006056A (ja) 2010-01-13 2015-07-07 ビタミンｄ関連化合物の１−デオキシ類似体
JP2015136520A Pending JP2016006055A (ja) 2010-01-13 2015-07-07 ビタミンｄ関連化合物の１−デオキシ類似体
JP2015136522A Pending JP2015212294A (ja) 2010-01-13 2015-07-07 ビタミンｄ関連化合物の１−デオキシ類似体

Country Status (3)

Country Link
US (3) US9775903B2 (enExample)
JP (4) JP5887672B2 (enExample)
WO (1) WO2011088209A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775903B2 (en) * 2010-01-13 2017-10-03 Johns Hopkins University 1-deoxy analogs of 1,25-dihydroxyvitamin D3 compounds
GB2512314A (en) * 2013-03-26 2014-10-01 Kartar Singh Lalvani Statin composition
CN105348163B (zh) * 2014-08-18 2017-06-16 武汉启瑞药业有限公司 维生素d类似物及其制备方法和医药用途
WO2018230711A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 ｍＴＯＲインヒビターを含む、眼の症状、障害または疾患を治療または予防するための医薬およびその応用
US20230398130A1 (en) * 2020-10-23 2023-12-14 Massachusetts Institute Of Technology Methods and compositions for differentiating stem cells
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830885A (en) 1992-03-12 1998-11-03 The Johns Hopkins University Antiproliferative vitamin D3 hybrids
DE60031666T2 (de) * 1999-04-01 2007-08-30 The Johns Hopkins University NICHT-CALCEMISCHE, TRANSKRIPTIONELL-AKTIVE, SCHWEFELHALTIGE ANALOGA VON 1-alpha, 25-DIHYDROXYVITAMIN D3 MIT ANTIPROLIFERATIVER WIRKUNG
WO2001028565A1 (en) * 1999-10-19 2001-04-26 Juichiro Nakayama Remedies for pigmentation and melanocyte proliferation inhibitors
JP2002104995A (ja) * 2000-09-29 2002-04-10 Masahiko Hosaka テロメラーゼ活性抑制剤
US7166585B2 (en) * 2001-08-22 2007-01-23 Cytochroma Inc. 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3
ES2283593T3 (es) 2001-10-12 2007-11-01 Johns Hopkins University Analogos de oxima poco calcemicos de 1alfa,25-dihidroxi vitamina d3.
AU2003233735A1 (en) 2002-06-13 2003-12-31 Cytochroma Inc. 24-sulfoximine vitamin d3 compounds
TWI286554B (en) * 2002-06-27 2007-09-11 Chugai Pharmaceutical Co Ltd Ferrocene compounds and uses thereof
WO2004037781A1 (en) * 2002-10-23 2004-05-06 Leo Pharma A/S Vitamin d analogues, compositions comprising said analogues and their use
WO2004054968A2 (en) * 2002-12-18 2004-07-01 Johns Hopkins University 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol)
EP1883626B1 (en) * 2005-04-25 2017-10-11 OPKO Ireland Global Holdings, Ltd. Low-calcemic 16,23-diene 25-oxime analogs of 1alpha,25-dihydroxy vitamin d3
JP4882050B2 (ja) * 2006-03-15 2012-02-22 日本マイクロバイオファーマ株式会社 インデン誘導体の製造方法およびその製造中間体
JP2009532458A (ja) 2006-04-06 2009-09-10 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１α−ヒドロキシ−１９，２１−ジノルビタミンＤ３類縁体およびその使用
US9775903B2 (en) * 2010-01-13 2017-10-03 Johns Hopkins University 1-deoxy analogs of 1,25-dihydroxyvitamin D3 compounds

Also Published As

Publication number Publication date
US20190060456A1 (en) 2019-02-28
JP2015212294A (ja) 2015-11-26
JP2016006055A (ja) 2016-01-14
US20130157987A1 (en) 2013-06-20
JP2016006056A (ja) 2016-01-14
WO2011088209A2 (en) 2011-07-21
US9775903B2 (en) 2017-10-03
US20180117156A1 (en) 2018-05-03
WO2011088209A3 (en) 2015-09-03
JP2013518812A (ja) 2013-05-23

Similar Documents

Publication Publication Date Title
US20190060456A1 (en) 1-deoxy analogs of vitamin d-related compounds
JP4493340B2 (ja) １α−ヒドロキシ−２−メチレン−１９−ノル−プレグナカルシフェロール及びその使用
JP5113766B2 (ja) ビタミンｄ類似体：ｒａｋ、その方法および使用
JP2009525980A (ja) ビタミンｄ類似体：ｎｅｌ、その方法および使用
AU2013375208B2 (en) (22E)-2-methylene-22-dehydro-1a,24,25-trihydroxy-19-nor-vitamin D3 analogs
HU211963A9 (en) Novel 1alpha-hydroxy vitamin d4 and novel intermediates and analogues
JP5043673B2 (ja) １７，２０（ｅ）−デヒドロビタミンｄ類似体およびそれらの使用
JP2008514621A (ja) ２０−シクロアルキル，２６，２７−アルキル／ハロアルキル−ビタミンｄ３化合物及びその使用方法
JP5036566B2 (ja) ２−メチレン−１９−ノル−（２０Ｓ−２４Ｓ）−１α，２５−ジヒドロキシビタミン−Ｄ２
JP5770261B2 (ja) （２０Ｓ）−２−メチレン−１９−ノル−２２−ジメチル−１α，２５−ジヒドロキシビタミンＤ３および（２０Ｒ）−２−メチレン−１９−ノル−２２−ジメチル−１α，２５−ヒドロキシビタミンＤ３
JP2008520709A (ja) ２−メチレン−１９−ノル−（２０Ｓ）−１α−ヒドロキシ−トリスホモプレグナカルシフェロール
JP5629682B2 (ja) ２−メチレン−（１７ｚ）−１７（２０）−デヒドロ−１９，２１−ジノル−ビタミンｄ類似物質
JP5036565B2 (ja) ２−メチレン−１９−ノル−（２０Ｓ−２４エピ）−１α，２５−ジヒドロキシビタミン−Ｄ２
NZ555562A (en) 2-methylene-19-nor-(20R)-1alpha-hydroxy-bishomopregnacalciferol
US20070054887A1 (en) Methods for treating bladder dysfunction
JP5449767B2 (ja) １α，２５−ジヒドロキシビタミンＤ３の低血漿カルシウム上昇性１６，２３−ジエン−２５−オキシムアナログ
MX2012005936A (es) 2-metilen-19,26-nor-(20s)-1a-hidroxivitamina d3.
JP5931845B2 (ja) ２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー
JP2021167319A (ja) カルシトリオールの２−メチレン類似体および関連化合物の合成および生物活性
JP4619360B2 (ja) ２−メチレン−１９−ノル−２０（Ｓ）−２５−メチル−１α−ヒドロキシカルシフェロール及びその使用
EP1898924A1 (en) Methods of treating osteoporosis and secondary hyperparathyroidism using 20-methyl, gemini vitamin d3 compounds
NZ555561A (en) 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol (a Vitamin D derivative)
WO2006035075A1 (en) Use of vitamin d compounds for the prevention or treatment of chronic prostatitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160128

R150 Certificate of patent or registration of utility model

Ref document number: 5887672

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees